Mounjaro: A New Option for Weight Loss

Hello.

This is Mutoel Plastic Surgery.

Recently, more and more people have been looking for various kinds of information in hospitals, pharmacies, and online communities for dieting.

At the center of that interest has been 'Wegovy,' the obesity treatment injection that has been the hottest topic recently.

However, among the recently developed obesity treatment injections, there is a product that has shown improved effects and minimized side effects compared with Wegovy, making it somewhat safer.

That product is an obesity treatment called 'Mounjaro.' To put it simply, this is also a medication administered as a once-weekly subcutaneous injection, and unlike conventional GLP-1-based medications (Wegovy, semaglutide), it is a dual agonist that simultaneously stimulates two receptors: GIP and GLP-1.

Thanks to this mechanism, it can induce appetite suppression, blood sugar control, and improved energy metabolism at the same time, and it is reported to show a relatively large weight loss effect.

That is why today, for those who are concerned while undergoing dieting, or for those who have been hesitant because of the side effects of existing products, we would like to explain in detail from the mechanism of action to comparisons with other products.

How does it work?

First, we need to understand the ingredients.

The main mechanism of GLP-1 receptor agonists is to slow gastric emptying, increase satiety, and promote insulin secretion to control blood sugar.

GIP is a hormone originally secreted in the small intestine, and it affects insulin secretion and fat metabolism.

Mounjaro activates these two pathways at the same time, improving weight loss effects, and some studies have shown superior weight loss (up to around 20%) compared with existing single agonists, demonstrating relatively strong efficacy.

Who uses it, and for what purpose?

It was originally developed as a treatment for type 2 diabetes, and later its use expanded as its strong weight loss effect was proven in obesity as well (based on BMI and other criteria).

It has also been approved and launched domestically and internationally for diabetes and obesity indications, and in recent years there have also been reported cases of discussion and approval in some countries as an adjunct treatment for sleep apnea.

In other words, it is a medication especially considered for patients who need both blood sugar control and weight loss, and it is a drug with excellent strengths in weight management.

In clinical trials (such as the SURMOUNT series), the Mounjaro group showed results in which, with long-term observation, average body weight decreased by more than 15% and up to over 20%,

and numerous reports showing a greater reduction rate than Wegovy (semaglutide) have been published, drawing significant attention.

Of course, individual responses vary greatly,

and results can differ substantially depending on whether lifestyle, diet, and exercise are combined.

How is it administered?

It is conveniently administered as a once-weekly subcutaneous injection (self-injectable pen) into the abdomen.

Usually, treatment starts with a low dose, and the dose is gradually increased every few weeks while checking for side effects, especially gastrointestinal adverse reactions, until the target dose is reached.

In the hospital, body weight, blood sugar, gastrointestinal symptoms, and drug interactions are monitored, and problems that arise as the dose is increased can be systematically analyzed and managed. Side effects and precautions

The most common side effects are the digestive symptoms mentioned above.

Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are most common at the beginning.

In many cases, these improve over time, but if the symptoms are severe, dose adjustment or discontinuation should be considered according to the specialist’s judgment.

Although rare, pancreatitis, gallstones, severe gastrointestinal symptoms, and hypoglycemia have also been reported, so careful observation by medical staff is essential.

In addition, use during pregnancy and breastfeeding is not recommended, and these risks and management methods should be explained after consulting with a specialist before prescribing, and it is important to proceed with the solution that is most appropriate for each individual.

What are the differences from Wegovy (semaglutide)?

Both treatments are GLP-1-based injectable medications that help with weight loss, but there are differences in how they work and their scope.

As briefly mentioned in the introduction, Wegovy is a single GLP agonist, while the tirzepatide ingredient in Mounjaro is a GIP+GLP-1 dual agonist, meaning the range of pathways involved is much broader.

Wegovy contains semaglutide and acts only on the GLP-1 receptor, reducing appetite and helping you feel full for longer.

On the other hand, Mounjaro contains tirzepatide, which simultaneously stimulates both GLP-1 and GIP receptors, so it is more actively involved not only in blood sugar control but also in fat metabolism, and research findings have reported that this leads to greater weight loss.

However, the greater the effect, the more important it is to gather data on side effect management, cost, and long-term outcomes.

To use it safely and effectively

Of course, every procedure and prescription medication can have side effects.

However, through careful observation and proper management, it is possible to improve effectiveness and reduce side effects.

First, we recommend clarifying your goal.

It is most important to clearly determine whether the reason you are starting treatment is for cosmetic purposes or to improve a metabolic disease, and to establish a long-term maintenance plan together with the attending medical staff rather than focusing only on short-term weight loss.

Also, side effects often occur early.

Gastrointestinal symptoms such as nausea may occur at the beginning, so if such symptoms appear, the dose should be gradually adjusted through communication with the medical staff.

Finally, lifestyle habits are, in my view, not a 'choice' but a 'necessity.'

To maximize the effect of the medication and prevent weight regain (yo-yo dieting), improvements in eating habits and exercise should be combined to reduce dependence on the medication. In closing...

Mounjaro is drawing significant attention in the medical field, showing such strong weight loss effects that it is being called a 'game changer' in the treatment of diabetes and obesity.

However, 'strong' also means that more careful patient selection and monitoring are needed.

It is most important to understand the pros and cons of the medication accurately and to plan safe treatment solutions together with a specialized medical team.

Depending on each person’s medical situation, what is the best option may differ, so we recommend consulting thoroughly with the responsible specialist before prescribing and then deciding whether to proceed.

This concludes the post from Yongsan Plastic Surgery, and we will return next time with even better information.

This was Mutoel Plastic Surgery.

Thank you.